Head of global clinical development for immunology/bone at UCB.
Assessing Phase 2 Data on Bepranemab’s Effect on Tau Accumulation and Cognitive Function: Matthew Barton, PhD
The head of global clinical development for immunology/bone at UCB talked about findings presented at CTAD 2024 from the phase 2 trial assessing bepranemab in Alzheimer disease. [WATCH TIME: 3 minutes]
Oligoclonal Bands in Cerebrospinal Fluid May Signal Higher Relapse Risk in MOGAD
M1 Modulatory TAK-091 Improves Cognition in Parkinson Disease, Study Shows
Navigating the Future of Gene Therapy in Neuromuscular Disorders: John Brandsema, MD
Exciting Innovations in Neurology to Come in 2025: Insights From Baptist Health